David Cuthbertson

List of Publications by Year
in descending order

90 papers	3,116 citations	159585 30 h-index	168389 53 g-index
94 all docs	94 docs citations	94 times ranked	3430 citing authors

#	Article	IF	Citations
1	A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	5.6	271
2	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Annals of the Rheumatic Diseases, 2012, 71, 1329-1334.	0.9	218
3	A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis. Arthritis and Rheumatology, 2017, 69, 846-853.	5.6	131
4	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody—Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1054-1066.	5.6	130
5	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. Journal of Rheumatology, 2015, 42, 1213-1217.	2.0	129
6	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Annals of the Rheumatic Diseases, 2014, 73, 1376-1379.	0.9	128
7	Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood, 2012, 120, 4945-4951.	1.4	126
8	Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet Journal of Rare Diseases, 2013, 8, 177.	2.7	117
9	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Seminars in Arthritis and Rheumatism, 2016, 45, 475-482.	3.4	109
10	Role of Insulin Resistance in Predicting Progression to Type 1 Diabetes. Diabetes Care, 2007, 30, 2314-2320.	8.6	94
11	Cardiac Involvement in Granulomatosis with Polyangiitis. Journal of Rheumatology, 2015, 42, 1209-1212.	2.0	87
12	A combined risk score enhances prediction of type 1 diabetes among susceptible children. Nature Medicine, 2020, 26, 1247-1255.	30.7	83
13	Identification of Susceptibility Loci in <i>IL6</i>, <i>RPS9</i>/<i>LILRB3</i>, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome‐Wide Association Study. Arthritis and Rheumatology, 2015, 67, 1361-1368.	5.6	79
14	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care and Research, 2020, 72, 1615-1624.	3.4	77
15	Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-Year TEDDY Study Progress Report. Diabetes Care, 2019, 42, 1051-1060.	8.6	75
16	Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial—Type 1. Diabetes Care, 2009, 32, 1603-1607.	8.6	59
17	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology, 2015, 54, 1351-1359.	1.9	52
18	Breastfeeding patterns of mothers with type 1 diabetes: results from an infant feeding trial. Diabetes/Metabolism Research and Reviews, 2010, 26, 206-211.	4.0	50

#	Article	IF	Citations
19	Safety and efficacy of autoantigen–specific therapy with 2 doses of alum–formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. Pediatric Diabetes, 2018, 19, 410-419.	2.9	45
20	Arterial lesions in giant cell arteritis: A longitudinal study. Seminars in Arthritis and Rheumatism, 2019, 48, 707-713.	3.4	43
21	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. Journal of Rheumatology, 2013, 40, 1905-1912.	2.0	40
22	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2020, 35, 283-291.	0.7	40
23	Performance of HbA1c as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. Diabetes Care, 2012, 35, 1821-1825.	8.6	39
24	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatology, 2013, 40, 674-683.	2.0	39
25	Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes. Diabetes Care, 2014, 37, 979-984.	8.6	37
26	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. Journal of Rheumatology, 2016, 43, 1078-1084.	2.0	37
27	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. Rheumatology, 2019, 58, 2203-2211.	1.9	37
28	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). PLoS ONE, 2015, 10, e0121737.	2.5	35
29	Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population. Diabetes Care, 2012, 35, 1975-1980.	8.6	34
30	Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. Genetics in Medicine, 2019, 21, 275-283.	2.4	34
31	Sequence–Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in *ADA2*. Arthritis and Rheumatology, 2021, 73, 512-519.	5.6	34
32	The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes. Diabetes Care, 2012, 35, 1552-1555.	8.6	33
33	A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. Clinical Genetics, 2018, 94, 502-511.	2.0	33
34	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. Rheumatology, 2020, 59, 1118-1127.	1.9	33
35	Biochemical markers and neuropsychological functioning in distal urea cycle disorders. Journal of Inherited Metabolic Disease, 2018, 41, 657-667.	3.6	31
36	Evaluation of damage in giant cell arteritis. Rheumatology, 2018, 57, 322-328.	1.9	28

#	ARTICLE	IF	CITATIONS
37	Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case–control ancillary study. Diabetologia, 2020, 63, 780-787.	6.3	28
38	Distinct Growth Phases in Early Life Associated With the Risk of Type 1 Diabetes: The TEDDY Study. Diabetes Care, 2020, 43, 556-562.	8.6	28
39	Patterns of clinical presentation in Takayasu's arteritis. Seminars in Arthritis and Rheumatism, 2020, 50, 576-581.	3.4	25
40	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis. Journal of Rheumatology, 2017, 44, 1529-1535.	2.0	25
41	A Multicenter Observational Cohort Study to Evaluate the Effects of Bisphosphonate Exposure on Bone Mineral Density and Other Health Outcomes in Osteogenesis Imperfecta. JBMR Plus, 2019, 3, e10118.	2.7	22
42	Clinical Manifestations and Long–Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. ACR Open Rheumatology, 2021, 3, 404-412.	2.1	21
43	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. Journal of Rheumatology, 2020, 47, 1001-1010.	2.0	20
44	Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk. Diabetologia, 2021, 64, 826-835.	6.3	18
45	Hearing loss in individuals with osteogenesis imperfecta in North America: Results from a multicenter study. American Journal of Medical Genetics, Part A, 2020, 182, 697-704.	1.2	17
46	Serum S100 Proteins as a Marker of Disease Activity in Large Vessel Vasculitis. Journal of Clinical Rheumatology, 2018, 24, 393-395.	0.9	16
47	Regional differences in milk and complementary feeding patterns in infants participating in an international nutritional type 1 diabetes prevention trial. Maternal and Child Nutrition, 2017, 13, .	3.0	15
48	Mobility in osteogenesis imperfecta: a multicenter North American study. Genetics in Medicine, 2019, 21, 2311-2318.	2.4	15
49	Pediatric Outcomes Data Collection Instrument is a Useful Patient-Reported Outcome Measure for Physical Function in Children with Osteogenesis Imperfecta. Genetics in Medicine, 2020, 22, 581-589.	2.4	14
50	Efficacy of leflunomide in the treatment of vasculitis. Clinical and Experimental Rheumatology, 2021, 39, 114-118.	0.8	14
51	Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: Results of a bone marrow failure consortium study. Leukemia Research, 2012, 36, 581-587.	0.8	13
52	A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatric Diabetes, 2011, 12, 85-90.	2.9	12
53	Association between family history, early growth and the risk of beta cell autoimmunity in children at risk for type 1 diabetes. Diabetologia, 2021, 64, 119-128.	6.3	12
54	Pregnancy in women with osteogenesis imperfecta: pregnancy characteristics, maternal, and neonatal outcomes. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100362.	2.6	11

#	ARTICLE	IF	CITATIONS
55	The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes. Diabetes, 2021, 70, 2922-2931.	0.6	11
56	Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS). Blood, 2008, 112, 221-221.	1.4	11
57	Serum fatty acids and risk of developing islet autoimmunity: A nested<scp>case–control</scp>study within the<scp>TRIGR</scp>birth cohort. Pediatric Diabetes, 2021, 22, 577-585.	2.9	10
58	Use of vitamin D supplements during infancy in an international feeding trial. Public Health Nutrition, 2014, 17, 810-822.	2.2	8
59	The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance. Diabetes Care, 2015, 38, 891-896.	8.6	8
60	Association of diabetes-related autoantibodies with the incidence of asthma, eczema and allergic rhinitis in the TRIGR randomised clinical trial. Diabetologia, 2020, 63, 1796-1807.	6.3	8
61	Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings: A Scoping Review, Meta-Analysis and Medical Chart Review. Cells, 2022, 11, 1891.	4.1	8
62	Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes. Diabetes Care, 2014, 37, 1959-1965.	8.6	6
63	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. PLoS ONE, 2018, 13, e0205768.	2.5	6
64	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. Journal of Rheumatology, 2019, 46, 928-934.	2.0	6
65	Increasing plasma glucose before the development of type 1 diabetes—the <scp>TRIGR</scp> study. Pediatric Diabetes, 2021, 22, 974-981.	2.9	6
66	Telomere length is not a main factor for the development of islet autoimmunity and type 1 diabetes in the TEDDY study. Scientific Reports, 2022, 12, 4516.	3.3	6
67	Effect of extensively hydrolyzed casein vs. conventional formula on the risk of asthma and allergies: The TRIGR randomized clinical trial. Pediatric Allergy and Immunology, 2021, 32, 670-678.	2.6	5
68	<scp>Health–related</scp> quality of life in adults with osteogenesis imperfecta. Clinical Genetics, 2021, 99, 772-779.	2.0	4
69	Growth differences between North American and European children at risk for type 1 diabetes. Pediatric Diabetes, 2012, 13, 425-431.	2.9	3
70	083.ƒCOMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASU'S ARTERITIS AND GIANT CELL ARTERITIS. Rheumatology, 2019, 58, .	1.9	3
71	Diabetic Ketoacidosis at the Time of Diagnosis of Type 1 Diabetes in Children. JAMA Pediatrics, 2021, 175, 518.	6.2	3
72	Large-Scale Prospective T Cell Function Assays in Shipped, Unfrozen Blood Samples: Experiences from the Multicenter TRIGR Trial. Vaccine Journal, 2014, 21, 203-211.	3.1	2

#	Article	IF	Citations
73	HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants. Diabetologia, 2022, 65, 88-100.	6.3	2
74	Hypothyroidism in vasculitis. Rheumatology, 2022, 61, 2942-2950.	1.9	2
75	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. Interactive Journal of Medical Research, 2022, 11, e27273.	1.4	2
76	First test effect in intravenous glucose tolerance testing. Pediatric Diabetes, 2015, 16, 129-137.	2.9	1
77	Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS). Blood, 2011, 118, 607-607.	1.4	1
78	An overview of the rare diseases clinical research network. Molecular Genetics and Metabolism, 2013, 108, S59.	1.1	0
79	148.â€ƒSHORT-FORM 36 AS A MEASURE OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GIANT CELL ARTERITIS. Rheumatology, 2019, 58, .	1.9	0
80	045.â€ƒEVALUATION OF NOVEL SERUM BIOMARKERS OF DISEASE ACTIVITY IN GIANT CELL ARTERITIS, TAKAYASUâ€™S ARTERITIS, POLYARTERITIS NODOSA, AND EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. Rheumatology, 2019, 58, .	1.9	0
81	020.â€ƒIDENTIFICATION OF TARGET ANTIGENS FOR ANTI-ENDOTHELIAL CELL ANTIBODIES IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS USING PROTEOMICS. Rheumatology, 2019, 58, .	1.9	0
82	043.â€ƒSUBGLOTTIC STENOSIS AND ENDOBRONCHIAL DISEASE IN GRANULOMATOSIS WITH POLYANGIITIS. Rheumatology, 2019, 58, .	1.9	0
83	035.â€ƒCANDIDATE BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS IDENTIFIED USING A PROTEOMIC APPROACH. Rheumatology, 2019, 58, .	1.9	0
84	084.â€ƒDISCOVERY AND VALIDATION OF A NOVEL ANGIOGRAPHIC CLASSIFICATION SCHEME IN TAKAYASUâ€™S ARTERITIS. Rheumatology, 2019, 58, .	1.9	0
85	138.â€ƒDIFFUSE ALVEOLAR HEMORRHAGE, PULMONARY NODULES AND INFILTRATES IN GRANULOMATOSIS POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. A COHORT STUDY OF 736 PATIENTS. Rheumatology, 2019, 58, .	1.9	0
86	Dietary compliance in a randomized doubleâ€blind infant feeding trial during infancy aiming at prevention of type 1 diabetes. Food Science and Nutrition, 2021, 9, 4221-4231.	3.4	0
87	<i>TCF7L2</i> Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes. Diabetes Care, 2021, 44, 2039-2044.	8.6	0
88	Elevated Fas Ligand and BA21 Serorecognition as Disease Correlates in Bone Marrow Failure Disorders: Taking Advantage of the LGL Leukemia Model.. Blood, 2007, 110, 4274-4274.	1.4	0
89	HTLV-1 Epitope (BA21) Reactivity in Rare Bone Marrow Failure Diseases. Blood, 2010, 116, 1724-1724.	1.4	0
90	Web-based surveys using Patient-Reported Outcome Measurement Information System (PROMIS) instruments allow documentation of important components of the disease experience among individuals with Osteogenesis Imperfecta. Bone Abstracts, 0, , .	0.0	0